Skip to search formSkip to main contentSkip to account menu

VX 950

Known as: VX-950, VX950 cpd 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

telaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2.
2011
2011
Selection of Clinically Relevant Protease Inhibitor-Resistant Viruses Using the Genotype 2a Hepatitis C Virus Infection System
ABSTRACT Treatment of patients infected with hepatitis C virus (HCV) with direct acting antivirals can lead to the emergence of… 
2011
2011
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
Summary.  The relationship of inhibitory quotient (IQ) with the virologic response to specific inhibitors of human hepatitis C… 
Review
2010
Review
2010
The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus
Importance of the field: Hepatitis C virus (HCV) is the main agent of chronic hepatitis, liver cirrhosis and hepatocellular… 
2009
2009
HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
2009
2009
Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.
2008
2008
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
Objective. Neopterin is a marker of monocyte/macrophage activity. Alanine aminotransferase (ALAT) is a marker of hepatocyte… 
2006
2006
Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.
HCV drug discovery efforts have largely focused on genotype 1 virus due to its prevalence and relatively poor response to current… 
2006
2006
737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a
2006
2006
28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)